Clinical Trial Update: Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of durvalumab with the FLOT chemotherapy regimen in resectable gastric and gastroesophageal junction cancers; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DOCETAXEL (DOCETAXEL)
• Durvalumab (durvalumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: AstraZeneca | Conditions: Gastrointestinal Neoplasms, Esophagogastric Junction | Phase 3 | Status: ACTIVE_NOT_RECRUITING